title: Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate.
abstract: This report describes three patients with chronic myelogenous leukemia who developed gastric antral vascular ectasia (GAVE) during treatment with imatinib mesylate (IM). Cessation and/or switching from IM to nilotinib resulted in the alleviation of gastrointestinal (GI) bleeding and ectatic lesions. Furthermore, GI bleeding recurred after the re-administration of IM in one patient. Thus, we consider that the occurrence of GAVE in our patients was induced by IM. Although the precise mechanism of IM-GAVE is not understood, all patients took at least 400 mg/day of IM at the onset of GAVE. Thus, higher doses of IM (≥400 mg/day) may be a risk factor for IM-GAVE.
authors.affiliation: Division of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Narukawa
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Kakihana
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Noriko
authors.initials: N
authors.lastname: Doki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Ohashi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D020252:Gastric Antral Vascular Ectasia / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib